Regulators approved the first bespoke cell therapies for solid tumors this year, while drugmakers expanded and improved upon ...

ADPA-2AFP is under clinical development by Adaptimmune Therapeutics and currently in Phase I for Pancreatic Cancer.

ADPA-2AFP is under clinical development by Adaptimmune Therapeutics and currently in Phase I for Neuroendocrine Tumors.

Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who ...

The challenges of infusion center scheduling Many infusion centers grapple with a predictable yet problematic pattern: a triangular demand profile. Mornings begin slowly, midday experiences a ...

This interview will appear in the January 2025 issue of Evidence-Based Oncology, our annual recap of the American Society of ...

Christians will make up 87% of voting members in the Senate and House of Representatives, combined, in the 119th Congress. That’s down from 88% in the last session and 92% a decade ago, but still far ...

After hours: January 3 at 6:22:49 PM EST Loading Chart for MD ...

Thank you for reporting this station. We will review the data in question. You are about to report this weather station for bad data. Please select the information that is incorrect.

One of the biggest matchups in NFL history is set to close the 2024 regular season.

*Two hours post–glucose load plasma venous glucose >7.8 mmol/L. †Fasting plasma venous glucose >6.1 mmol/L or 2-hour post–glucose load plasma venous glucose >11.1 mmol/L. ‡Highest quartile fasting ...